Free Trial

Merck KGaA (MKGAF) Stock Forecast & Price Target

Merck KGaA logo
$142.05 -3.01 (-2.08%)
(As of 11/20/2024 ET)

Merck KGaA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
1

Based on 1 Wall Street analysts who have issued ratings for Merck KGaA in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 1 analysts, 1 has given a strong buy rating for MKGAF.

Consensus Price Target

N/A

Get the Latest News and Ratings for MKGAF and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Merck KGaA and its competitors.

Sign Up

MKGAF Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
N/A N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
N/A N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
N/A N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
N/A N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Strong Buy
Strong Buy
N/AN/A

MKGAF Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MKGAF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Merck KGaA Stock vs. The Competition

TypeMerck KGaAMedical CompaniesS&P 500
Consensus Rating Score
4.00
2.80
2.50
Consensus RatingStrong BuyModerate BuyModerate Buy
Predicted UpsideN/A26,931.57% Upside9.83% Upside
News Sentiment Rating
Positive News

See Recent MKGAF News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/19/2024The Goldman Sachs Group
2 of 5 stars
J. Quigley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:20 AM ET.


MKGAF Forecast - Frequently Asked Questions

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There is currently 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" MKGAF shares.

According to analysts, Merck KGaA's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Merck KGaA's stock had 1 upgrade by analysts.

Merck KGaA has been rated by research analysts at The Goldman Sachs Group in the past 90 days.

Analysts like Merck KGaA more than other "medical" companies. The consensus rating for Merck KGaA is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MKGAF compares to other companies.


This page (OTCMKTS:MKGAF) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners